Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.59USD
22 Jun 2018
Change (% chg)

$-0.18 (-3.12%)
Prev Close
$5.77
Open
$5.77
Day's High
$5.77
Day's Low
$5.35
Volume
623,221
Avg. Vol
233,962
52-wk High
$6.67
52-wk Low
$3.95

Chart for

About

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $551.83
Shares Outstanding(Mil.): 98.72
Dividend: --
Yield (%): --

Financials

  BCRX.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -0.85 -- --
ROI: -102.45 -5.25 13.10
ROE: -153.78 -6.83 15.09

BRIEF-Biocryst Pharmaceuticals Q1 Loss Per Share $0.26

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

May 08 2018

BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza

* BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger

April 10 Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :

Apr 10 2018

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

Apr 02 2018

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

Apr 02 2018

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

Apr 02 2018

BRIEF-Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema

* BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA

Mar 15 2018

BRIEF-Biocryst Reports Q4 Loss Per Share of $0.20

* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

Feb 16 2018

BRIEF-Great Point Reports 7.60 Pct Stake In BioCryst Pharmaceuticals

* GREAT POINT PARTNERS, LLC REPORTS 7.60 PERCENT STAKE IN BIOCRYST PHARMACEUTICALS INC AS OF FEBRUARY 6, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2HjJO7H) Further company coverage:

Feb 16 2018

Competitors

Earnings vs. Estimates